Structural and neurochemical markers of brain injury in the migraine diathesis of systemic lupus erythematosus.
OBJECTIVE
To determine whether migraine in systemic lupus erythematosus (SLE) is associated with accentuated brain injury and disease activity.


METHODS
Forty SLE patients (11 without headache, 11 with non-migraine headache, and 18 with migraine) underwent clinical evaluation, magnetic resonance imaging (MRI), and spectroscopy (MRS).


RESULTS
Recurrent headache occurred in 75% of SLE patients. MRI abnormalities and reduced N-acetylaspartate were common. However, migraine in SLE was not associated with increased disease activity or severity, neuropsychiatric manifestations, or end-organ involvement compared to patients without migraine (p > 0.05). There were no differences in the prevalence or severity of MRI or MRS abnormalities between SLE patients with migraine, with non-migraine headache, or without headache (p > 0.05).


CONCLUSIONS
Headache does not identify SLE patients at risk for brain injury, increased disease activity, or increased end-organ involvement. Aggressive immunosuppressive therapy for headache alone is not indicated in SLE.
Rozell
C L
CL
Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, USA.
Sibbitt
W L
WL
Brooks
W M
WM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D001921:Brain / Q000473:pathology / Q000503:physiopathology; D001927:Brain Diseases / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology*; D015331:Cohort Studies; D004198:Disease Susceptibility / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology*; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008875:Middle Aged; D008881:Migraine Disorders / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology*; D012307:Risk Factors
D001224:Aspartic Acid; C000179:N-acetylaspartate